Skip to main content

A phase 1b study of mavorixafor, an oral CXCR4 antagonist, in combination with ibrutinib in patients with waldenstrom's macroglobulinemia expressing mutations in MYD88 and CXCR4

X4 Pharmaceuticals

X4 Pharmaceuticals


TAP Partner

Project Term: April 12, 2019 - TBD

In April 2019, LLS entered into a partnership with X4 Pharmaceuticals to support "A Phase 1b Trial of Mavorixafor, an Oral CXCR4 Antagonist, in Combination With Ibrutinib in Patients With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4." The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia.

Lay Abstract

For additional information, please visit

Therapy Acceleration Program
To All Projects